StockNews.com lowered shares of Amarin (NASDAQ:AMRN - Free Report) from a hold rating to a sell rating in a research report report published on Tuesday.
Amarin Trading Down 1.7 %
Shares of Amarin stock traded down $0.01 during mid-day trading on Tuesday, reaching $0.54. 803,505 shares of the stock were exchanged, compared to its average volume of 1,061,441. The company has a market cap of $222.54 million, a price-to-earnings ratio of -6.02 and a beta of 1.83. The firm has a 50-day simple moving average of $0.55 and a 200 day simple moving average of $0.56. Amarin has a fifty-two week low of $0.43 and a fifty-two week high of $1.25.
Institutional Investors Weigh In On Amarin
Hedge funds have recently made changes to their positions in the company. Arkfeld Wealth Strategies L.L.C. increased its position in shares of Amarin by 52.6% during the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 20,000 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Amarin during the 4th quarter worth about $36,000. China Universal Asset Management Co. Ltd. grew its holdings in Amarin by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 29,992 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its holdings in Amarin by 80.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 42,700 shares during the last quarter. Finally, Generation Capital Management LLC bought a new stake in Amarin during the 4th quarter worth about $50,000. Institutional investors and hedge funds own 22.25% of the company's stock.
Amarin Company Profile
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Featured Articles
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
